How a Little-Known Glycoprotein Blocks a Cancer Cell’s Immune Response

January 28, 2021

 • 

Read time:

5-15 mins
Share on facebook
Share on twitter
Share on reddit
Share on email
Share on print
Interaction Between STC1 And CRT Within A Cell Gatewayextension
Share on facebook
Share on twitter
Share on reddit
Share on email
Share on print
Presented by Health Lab

The University of Michigan Rogel Cancer Center team recently analyzed more than one thousand genes to determine why some cancer immunotherapy treatments work only for a smaller number of patients. They zoned in on one that came up in patients and mouse models that did not respond to immune checkpoint therapy.

More from the Alumni Education Gateway
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.